Literature DB >> 6820904

[Concentration of 5-FU level in the tissue and blood of the patients with breast cancer by preoperative administration of UFT].

K Suemasu, C Nomoto, Y Higashi.   

Abstract

A preoperative adjuvant chemotherapy for the prevention of recurrence of breast cancer is necessary. We administrated UFT orally at 600 mg/day to 87 patients with primary breast cancer and measured the 5-FU level in the tissue and blood. The mean blood level of 5-FU after administration was 0.073 mcg/ml at one hr, 0.081 mcg/ml at 2 hrs, 0.043 mcg/ml at 3 hrs and remained significantly after 5 hrs (0.031 mcg/ml). The mean 5-FU level in the dominant vessels of the breast was also significantly high. The mean tumor 5-FU level was 0.22 mcg/g (0.025-0.768) and normal breast tissue level was 0.048 mcg/g (0.011-0.394). This showed significantly high tumor 5-FU level compared with that of normal (p less than 0.001). In comparison of 5-FU levels with tumor sizes of T1, T2 and T3 and histological patterns (papillotubular, medullary tubular and scinhous) not significant difference was observed. The mean metastatic lymph node level of 5-FU was 0.193 mcg/g (0.070-0.789) and normal lymph node level was 0.093 mcg/g (0.008-0.210) (p less than 0.05). In conclusion, preoperative administration of UFT was considered to be very effective for the primary breast cancer because of high tumor affinity of 5-FU.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6820904

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  5 in total

1.  Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.

Authors:  R Pazdur; Y Lassere; E Diaz-Canton; B Bready; D H Ho
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 2.  Oral tegafur/uracil.

Authors:  K Wellington; K L Goa
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 3.  Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil.

Authors:  P M Hoff; Y Lassere; R Pazdur
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 4.  Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions.

Authors:  Eric D Eisenmann; Zahra Talebi; Alex Sparreboom; Sharyn D Baker
Journal:  Basic Clin Pharmacol Toxicol       Date:  2021-06-28       Impact factor: 4.080

5.  'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.

Authors:  J Bennouna; H Perrier; B Paillot; F Priou; J H Jacob; M Hebbar; S Bordenave; J F Seitz; F Cvitkovic; E Dorval; K Malek; D Tonelli; J Y Douillard
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.